ロシュのカンファレンスコールより。
ゾフルーザ押し全開でした。


Turning the attention to baloxavir in Influenza A 、B, we presented some data recently of the IDWeek.

And this is the second trial to read out the so-called CAPSTONE-2, which is in people at high risk of complications of influenza.

Baloxavir, as you know is a first-in-class small molecule inhibitor of viral RNA and a single dose regimen we already presented the CAPSTONE-1 data,

which is the substance of our filing right now with the PDUFA date at the end of the year and uncomplicated influenza.

And now with this trial, the first really antiviral to show in effect in people with high risk complications,

this is now the second trial to show a significant antiviral activity and potentially reduced transmission rates.

So, note in this table and the fact that the efficacy in type B is significantly better compared to Tamiflu and reduced time to viral shedding was almost half

compared to Tamiflu as well as reduced use of systematic antibodies and influenza related complications.

So, very consistent with CAPSTONE-1 and where it become more and more convinced that this is a medicine that will improve on almost all aspects of Tamiflu going forward.





参考
Roche Holding Ltd (RHHBY) CEO Severin Schwan on Q3 2018 Results - Earnings Call Transcript
Oct. 17, 2018 11:06 PM

https://seekingalpha.com/article/4212292-roche-holding-ltd-rhhby-ceo-severin-schwan-q3-2018-results-earnings-call-transcript